Literature DB >> 3567019

Enantiomers of warfarin and vitamin K1 metabolism.

I A Choonara, B P Haynes, S Cholerton, A M Breckenridge, B K Park.   

Abstract

The effect of the individual enantiomers of warfarin at steady state (1 mg daily) was investigated in five healthy volunteers. Both enantiomers produced a significant increase in prothrombin time, but the increase with S warfarin (1.8 +/- 0.8 s, mean +/- s.d.) was greater than with R warfarin (1.0 +/- 0.3 s), despite lower steady state plasma concentrations of S warfarin, due to its more rapid clearance. Following the administration of vitamin K1, the maximum plasma concentration and area under the plasma concentration time curve values for the metabolite vitamin K1 2,3-epoxide were greater after S warfarin than after R warfarin. The greater anticoagulant potency of S warfarin is reflected by a greater degree of inhibition of vitamin K1 epoxide reductase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3567019      PMCID: PMC1401216          DOI: 10.1111/j.1365-2125.1986.tb02966.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Differential effect of the enantiomers of phenprocoumon and warfarin on the vitamin K1-epoxide/vitamin K1 ratio in rat plasma.

Authors:  W Schmidt; D Beermann; F Oesch; E Jähnchen
Journal:  J Pharm Pharmacol       Date:  1979-07       Impact factor: 3.765

2.  Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man.

Authors:  M J Shearer; A McBurney; A M Breckenridge; P Barkhan
Journal:  Clin Sci Mol Med       Date:  1977-06

3.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

4.  Warfarin and the inhibition of vitamin K activity by an oxide metabolite.

Authors:  R G Bell; J T Matschiner
Journal:  Nature       Date:  1972-05-05       Impact factor: 49.962

5.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.

Authors:  A Breckenridge; M Orme; H Wesseling; R J Lewis; R Gibbons
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

6.  Quantitative analysis of pharmacological levels of vitamin K1 and vitamin K1 2,3-epoxide in rabbit plasma by high-performance liquid chromatography.

Authors:  A C Wilson; B K Park
Journal:  J Chromatogr       Date:  1983-10-14

7.  Plasma disposition of vitamin K1 in relation to anticoagulant poisoning.

Authors:  B K Park; A K Scott; A C Wilson; B P Haynes; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

8.  Inhibition by warfarin enantiomers of prothrombin synthesis, protein carboxylation, and the regeneration of vitamin K from vitamin K epoxide.

Authors:  R G Bell; P Ren
Journal:  Biochem Pharmacol       Date:  1981-07-15       Impact factor: 5.858

9.  Mechanism of action of anticoagulants: correlation between the inhibition of prothrombin synthesis and the regeneration of vitamin K1 from vitamin K1 epoxide.

Authors:  P Ren; P Y Stark; R L Johnson; R G Bell
Journal:  J Pharmacol Exp Ther       Date:  1977-06       Impact factor: 4.030

10.  Stereoselective interaction between the R enantiomer of warfarin and cimetidine.

Authors:  I A Choonara; S Cholerton; B P Haynes; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

View more
  13 in total

1.  Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation.

Authors:  Karla Claudio-Campos; Mariangeli Moneró-Paredes; Eliud Hernández; Jessicca Renta; Jorge Duconge
Journal:  Pharmacogenomics       Date:  2019-08       Impact factor: 2.533

2.  Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy.

Authors:  Marco Bontempi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-15       Impact factor: 2.745

3.  Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Shasha Jin; Zhihong Li; Qing Yang; Boyu Fang; Xiaoqiang Xiang; Chao Peng; Weimin Cai
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

4.  A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Authors:  Jamil A Haque; Matthew G McDonald; John D Kulman; Allan E Rettie
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

Review 5.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

6.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 7.  Stereoisomers and drug toxicity. The value of single stereoisomer therapy.

Authors:  A K Scott
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

8.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.

Authors:  E Chan; A J McLachlan; M Pegg; A D MacKay; R B Cole; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

9.  Chiral liquid chromatography-tandem mass spectrometry analysis of superwarfarin rodenticide stereoisomers - Bromadiolone, difenacoum and brodifacoum - In human plasma.

Authors:  Daniel G Nosal; Douglas L Feinstein; Richard B van Breemen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-01-07       Impact factor: 3.318

10.  Separation and Quantification of Superwarfarin Rodenticide Diastereomers-Bromadiolone, Difenacoum, Flocoumafen, Brodifacoum, and Difethialone-in Human Plasma.

Authors:  Daniel G Nosal; Douglas L Feinstein; Luying Chen; Richard B van Breemen
Journal:  J AOAC Int       Date:  2020-06-01       Impact factor: 2.028

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.